Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
UBS
Harvard Business School
Cerilliant
US Department of Justice
McKinsey
Fish and Richardson
Boehringer Ingelheim
Cipla

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,435,427

« Back to Dashboard

Which drugs does patent 7,435,427 protect, and when does it expire?

Patent 7,435,427 protects ABSORICA and is included in one NDA.

This patent has ten patent family members in eight countries.
Summary for Patent: 7,435,427
Title:Pharmaceutical semi-solid composition of isotretinoin
Abstract: An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle.
Inventor(s): Vanderbist; Francis (Beersel, BE), Servais; Cecile (Malonne, BE), Baudier; Philippe (Uccle, BE)
Assignee: Galephar M/F (Marche-en-Famenne, BG)
Application Number:10/380,619
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use; Process;

Drugs Protected by US Patent 7,435,427

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-001 May 25, 2012 BX RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-002 May 25, 2012 BX RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-005 Aug 15, 2014 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-003 May 25, 2012 BX RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-006 Aug 15, 2014 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Sun Pharm Inds Inc ABSORICA isotretinoin CAPSULE;ORAL 021951-004 May 25, 2012 BX RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,435,427

PCT Information
PCT FiledSeptember 21, 2001PCT Application Number:PCT/BE01/00163
PCT Publication Date:March 28, 2002PCT Publication Number: WO02/24172

Non-Orange Book US Patents Family Members for Patent 7,435,427

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,367,102 Pharmaceutical semi-solid composition of isotretinoin ➤ Sign Up
9,089,534 Pharmaceutical semi-solid composition of isotretinoin ➤ Sign Up
8,952,064 Pharmaceutical semi-solid composition of isotretinoin ➤ Sign Up
9,078,925 Pharmaceutical semi-solid composition of isotretinoin ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,435,427

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal 1318791 ➤ Sign Up
Spain 2225600 ➤ Sign Up
European Patent Office 2964195 ➤ Sign Up
European Patent Office 1318791 ➤ Sign Up
Germany 60104206 ➤ Sign Up
Canada 2836228 ➤ Sign Up
Canada 2423170 ➤ Sign Up
Australia 8943801 ➤ Sign Up
Austria 270544 ➤ Sign Up
World Intellectual Property Organization (WIPO) 0224172 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Johnson and Johnson
Merck
Chinese Patent Office
Mallinckrodt
Cantor Fitzgerald
Federal Trade Commission
Harvard Business School
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot